Literature DB >> 7730221

Synergic inhibitory activity of amphotericin-B and gamma interferon against intracellular Cryptococcus neoformans in murine macrophages.

J L Herrmann1, N Dubois, M Fourgeaud, D Basset, P H Lagrange.   

Abstract

Cryptococcus neoformans is responsible for pulmonary and meningal infections in HIV patients. The lack of effective cellular cooperation caused by the low level of CD4+ cells, and the resistance of C. neoformans to phagocytosis allows growth and persistence of the yeast in the host. We describe here an in-vitro model of intracellular replication of C. neoformans inside J774-A.1 macrophages, and the determination of the intracellular antifungal activity of amphotericin B and fluconazole alone or in association with IFN-gamma. The maximum inhibitory effect was observed with one MIC of amphotericin B and 100 or 1000 IU/mL of IFN-gamma. amphotericin B alone (at 1 x MIC), or either 1 x or 50 x MIC of fluconazole in normal or IFN-gamma activated macrophages, did not eradicate the ingested yeast. A potential underlying mechanism of the synergy of amphotericin B in IFN-gamma primed macrophages was investigated by measurement of nitrite level and by use of the NO synthase competitive inhibitor, NG-monomethyl L-arginine (NMMA). One MIC of amphotericin B was able to activate the synthesis of nitrogen reactive intermediates in IFN gamma-primed macrophages. NMMA treated infected macrophages responded less well to IFN-gamma priming, resulting in a moderate inhibition in subsequent amphotericin B exposure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7730221     DOI: 10.1093/jac/34.6.1051

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.

Authors:  Katie L Propst; Ryan M Troyer; Lisa M Kellihan; Herbert P Schweizer; Steven W Dow
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

3.  Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.

Authors:  M Larabi; P Legrand; M Appel; S Gil; M Lepoivre; J Devissaguet; F Puisieux; G Barratt
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Benzothiourea Derivatives Target the Secretory Pathway of the Human Fungal Pathogen Cryptococcus neoformans.

Authors:  Sarah R Beattie; Nicholas J Schnicker; Thomas Murante; Kavitha Kettimuthu; Noelle S Williams; Lokesh Gakhar; Damian J Krysan
Journal:  ACS Infect Dis       Date:  2020-02-26       Impact factor: 5.084

5.  Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection.

Authors:  T Kuhara; K Uchida; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

6.  A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.

Authors:  Arielle Butts; Louis DiDone; Kristy Koselny; Bonnie K Baxter; Yeissa Chabrier-Rosello; Melanie Wellington; Damian J Krysan
Journal:  Eukaryot Cell       Date:  2012-12-14

7.  Structure-activity relationships for the antifungal activity of selective estrogen receptor antagonists related to tamoxifen.

Authors:  Arielle Butts; Jennifer A Martin; Louis DiDone; Erin K Bradley; Mitchell Mutz; Damian J Krysan
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

Review 8.  Optimizing efficacy of Amphotericin B through nanomodification.

Authors:  Gillian Barratt; Stéphane Bretagne
Journal:  Int J Nanomedicine       Date:  2007

9.  Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.

Authors:  Arielle Butts; Kristy Koselny; Yeissa Chabrier-Roselló; Camile P Semighini; Jessica C S Brown; Xuying Wang; Sivakumar Annadurai; Louis DiDone; Julie Tabroff; Wayne E Childers; Magid Abou-Gharbia; Melanie Wellington; Maria E Cardenas; Hiten D Madhani; Joseph Heitman; Damian J Krysan
Journal:  MBio       Date:  2014-02-11       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.